MRSA, VRE, KPC, ESBL multiple drug resistant organism are showing up in healthcare facilities and in the community. What do you need to know?
FDA currently reviewing the ability of VESTEX® to reduce COVID-19. While the FDA has not yet reviewed the ability of products protected by VESTEX® to reduce COVID-19, preliminary research has documented results equal to or better than the reduction of MRSA. This research is being assessed analytically and VESTEX® does intend to seek FDA clearance for specific claims […]
Don’t risk taking body fluids, bacteria or viruses home anymore. VESTEX is the company to go to. They are approved by the FDA and work the way advertise. They are worth every penny. Tried, Tested and Loved. The global VESTEX® brand franchise has been in development for over a decade. For thousands of consumers around the […]
https://www.infectioncontroltoday.com/view/how-infection-preventionists-or-nurses-work-better-together
Author – John Jernigan, M.D., director of CDC’s Office of Prevention Research and Evaluation and head of CDC’s Prevention Epicenters Program. I am excited to announce the results of the REDUCE MRSA study which evaluated three current strategies f…
Susan Huang, M.D., M.P.H., lead author of the REDUCE MRSA study and Associate Professor at the University of California Irvine School of Medicine and Medical Director of Epidemiology and Infection Prevention at UC Irvine Health For years, we have searc…
The REDUCE MRSA trial was published in today’s New England Journal of Medicine and took place in two stages from 2009-2011. A multidisciplinary team from the University of California, Irvine, Harvard Pilgrim Health Care Institute, Hospital Corporatio…
Author: John Jernigan, M.D Director for CDC’s Office of HAI Prevention Research and Evaluation, Division of Healthcare Quality Promotion The optimal approach to controlling MRSA in healthcare facilities has been a topic of ongoing controversy. Of par…
Colonization vs Infection Colonization is the presence, growth, and multiplication of the organism without observable clinical symptoms or immune reaction. 1. MRSA – Colonization may occur in: the nares; axillae; chronic wounds or decubitus ulcer surface; perineum; around gastrostomy and tracheostomy sites; in the sputum or urine; and on healthy skin. One of the […]
Gram-negative bacilli have been a source of healthcare-associated infections for many years and may be found in patients in virtually all healthcare settings as either infection or colonization. In recent years, multidrug-resistant gram-negative organisms have increased in nearly all healthcare settings. Though resistance to any class of antibiotic can occur, it occurs mainly among […]
Vancomycin-resistant enterococci were initially reported in 1986 in Europe. In the last two decades enterococci have become recognized as a leading cause of healthcare associated bacteremia, surgical wound infection, and urinary tract infection. According to the National Nosocomial Infection Surveillance System (NNIS), prior to 1990 the occurrence of VRE infections in ICU’s in the U.S. […]
Methicillin-resistant S. aureus is a variant of S. aureus which is considered to be resistant to all beta-lactam antibiotics (including penicillins, cephalosporins, and cephamicins). It may also be resistant to one or more other classes of antibiotics. By definition, MRSA must be resistant to one of the following semi-synthetic penicillins: methicillin, oxacillin, or nafcillin. Treatment […]
Community-Associated MRSA has emerged in the general population as a frequent cause of skin infections (boils, abscesses, furuncles, etc.), and occasionally more invasive infections in healthy individuals lacking the usual risk factors for bacterial infection. Outbreaks of CA-MRSA have been described in numerous community settings and among varied population. CA-MRSA is most frequently transmitted when […]
August 11,2010 Jama reported that from 2005 through 2008, there were 21503 episodes of invasive MRSA infections; 17508 were health care associated. Of these, 15,458 were MRSA bloodstream infections. The incidence rate of hospital-onset invasive MRSA infections was 1.02 per 10,000 population in 2005 and decreased 9.4% per year (95% confidence interval [Cl], 14.7% to […]